Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin

This publication has 23 references indexed in Scilit:

• Multiple pathways of cell invasion are regulated by multiple families of serine proteases
  Clinical & Experimental Metastasis, 2002
• N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl)doxorubicin: An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity
  Journal of Medicinal Chemistry, 2001
• Unraveling the role of proteases in cancer
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 2000
• Superior therapeutic efficacy of N-l-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug
  European Journal Of Cancer, 1999
• Cloning and Functional Expression of a Metalloendopeptidase from Human Brain with the Ability to Cleave a β-APP Substrate Peptide
  Biochemical and Biophysical Research Communications, 1995
• Rat thimet oligopeptidase: large-scale expression in Escherichia coli and characterization of the recombinant enzyme
  Biochemical Journal, 1995
• Characterization of a Mitochondrial Metallopeptidase Reveals Neurolysin as a Homologue of Thimet Oligopeptidase
  Published by Elsevier ,1995
• Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
  Clinical Pharmacology & Therapeutics, 1992
• Structure/function relationships in the inhibition of thimet oligopeptidase by carboxyphenylpropyl‐peptides
  FEBS Letters, 1991
• Substrate-related potent inhibitors of brain metalloendopeptidase
  Biochemistry, 1988